AVDL

AVDL

USD

Avadel Pharmaceuticals plc Ordinary Share

$18.780+0.030 (0.160%)

Real-time Price

Healthcare
Drug Manufacturers - Specialty & Generic
Ireland

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$18.750

High

$18.780

Low

$18.680

Volume

1.08M

Company Fundamentals

Market Cap

1.8B

Industry

Drug Manufacturers - Specialty & Generic

Country

Ireland

Trading Stats

Avg Volume

2.43M

Exchange

NGM

Currency

USD

52-Week Range

Low $6.38Current $18.780High $19.06

Related News

Analyst Upgrades

UBS Downgrades Avadel Pharmaceuticals to Neutral, Maintains Price Target to $20

UBS analyst Ashwani Verma downgrades Avadel Pharmaceuticals from Buy to Neutral and maintains the price target from $20 to $20.

View more
UBS Downgrades Avadel Pharmaceuticals to Neutral, Maintains Price Target to $20
Analyst Upgrades

Leerink Partners Downgrades Avadel Pharmaceuticals to Market Perform, Announces $18.5 Price Target

Leerink Partners analyst Marc Goodman downgrades Avadel Pharmaceuticals from Outperform to Market Perform and announces $18.5 price target.

View more
Leerink Partners Downgrades Avadel Pharmaceuticals to Market Perform, Announces $18.5 Price Target
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

View more
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)
PR Newswire

HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

View more
HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM
Analyst Upgrades

Jefferies Downgrades Avadel Pharmaceuticals to Hold, Lowers Price Target to $20

Jefferies analyst Andrew Tsai downgrades Avadel Pharmaceuticals from Buy to Hold and lowers the price target from $22 to $20.

View more
Jefferies Downgrades Avadel Pharmaceuticals to Hold, Lowers Price Target to $20
Analyst Upgrades

Needham Downgrades Avadel Pharmaceuticals to Hold

Needham analyst Ami Fadia downgrades Avadel Pharmaceuticals from Buy to Hold.

GlobeNewswire

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all